Connect with us

Spread & Containment

Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch

Short squeeze penny stocks to watch this week.
The post Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch appeared first on Penny Stocks to…



There are plenty of ways to find the best penny stocks to buy. The first step, however, is knowing your idea of “best.” Everyone has a different style of trading and investing they subscribe to.

Some look for entry opportunities to buy penny stocks and hold them long-term. Others want to be in and out within minutes or hours by day trading cheap stocks. Ultimately, the decision is up to you, and it comes down to what’s on your penny stocks watch list that matters.

One of the ways to create a list is to find a theme that fits your trading strategy. This might include things like “high volume penny stocks” or stocks with big news. Today’s article looks at a list of penny stocks with higher short interest. This trend has become popular over the last two years thanks to the historical rise in the price of shares of meme stocks like AMC Entertainment and GameStop.

How To Find Short Squeeze Stocks

One of the ways to find short-squeeze stocks is to identify higher short interest. You see, one of the ways traders make money when stocks go down is by shorting them. This involves borrowing shares from your broker, selling them in the open market, observing a decline in share price, repurchasing shares at the lower price, and then returning your loan. The money is made from the difference in price between the initial selling price and the final repurchase price.

But when the stock prices rise instead of fall, it can trigger a squeeze. Traders who are shorting still need to repay their loans. When prices rise, they buy back for a loss. As more short-cover buying adds to the already bullish retail trading in the market, that can spark a snowball effect. While they are extreme examples, this is where GME and AMC stocks have shown how wild a short squeeze can get.

There aren’t any guarantees that high short-interest stocks will squeeze. But the first place to research is by looking for stocks that meet those criteria. This article continues the list of penny stocks in our article Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch.

High Short-Interest Penny Stocks

Redfin Corp. (RDFN)

As many of you understand, the housing market has cooled off. For those who may not know, Redfin is one of the more popular real estate trading marketplaces buyers and sellers use to connect. It’s no secret that Redfin and many other related companies have faced plenty of headwinds over the past few months. Rising interest rates and a hawkish Fed haven’t helped sentiment either.

Redfin recently indicated that the supply of homes for sale continues to rise. Late last month, the company said this figure jumped 18% during the four weeks ending December 25th. This was the most significant uptick since 2015, according to Redfin. The company also released data this week showing a record share of sellers are now giving concessions to buyers.

Penny Stocks To Buy In 2023? 3 To Watch In January

“Buyers are asking sellers for things that were unheard of during the past few years,” said Van Welborn, a Redfin real estate agent in Phoenix. “They’re feeling empowered, partly because their offer is often the only one, and partly because they know sellers have built up so much equity during the pandemic that they can afford to dole out sizable concessions.”

What To Watch With RDFN Stock

In the meantime, home sales continue to jump under certain circumstances. For instance, in a late-December report, Redfin cited all-cash purchases. Homes bought without financing mechanisms increased the highest since 2014. Nevertheless, depressed prices have sparked attention on RDFN stock’s short interest. Fintel.IO has this figure sitting around 18.86%

AST SpaceMobile, Inc. (ASTS)

Another one of the penny stocks experiencing renewed bullish interest is AST SpaceMobile. The company is building a space-based cellular broadband network directly accessible by mobile phones. In an operations update last month, AST outlined several initiatives underway.

In particular, its BlueWalker 3, Block 1 BlueBird, and BlueBird programs were highlighted. “The achievements to date for BlueWalker 3 validate the design roadmap for our BlueBirds, including deploying and flying the largest-ever commercial communications array in low Earth orbit, a key fundamental and patented technology to deliver space-based cellular broadband directly to unmodified phones,” said Abel Avellan, Chairman and CEO of AST SpaceMobile.

What To Watch With ASTS Stock

Now the focus is on this quarter. AST also explained that thanks to the successful deployment of BlueWalker 3’s communications array, it will begin testing with mobile network operators in Q1, 2023. With this backdrop, some look for signs of a reversal in ASTS stock. Part of the focus is on the current short interest. Fintel has this figure showing at roughly 22%.

Imara Inc. (IMRA)

Shares of Imara Inc have been on fire since September thanks to news of an initial asset purchase agreement with Cardurion Pharmaceuticals. It agreed to sell its Tovinontrine and other program assets for over $35 million upfront and options for another $60 million in milestones. At the time of that news, IMRA stock traded below $1.50.

Fast-forward to this week, and the penny stock now trades closer to $5. Though not much news has come from the company recently, there are a few things to keep track of. One of the foremost has been completing a previously announced merger with Enliven Therapeutics. The oncology treatment development company and Imara announced intentions to combine at the start of the third quarter. Since then, customary closing steps have been working themselves out.

Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now

According to the companies, “the combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001…in the treatment of chronic myeloid leukemia (CML), and ELVN-002…for the treatment of HER2 mutant lung cancer and other HER2-driven tumor types.”

What To Watch With IMRA Stock

Following the merger, the surviving company would be Enliven, and it would trade under the ticker ELVN. With the process continuing, there’ve been some interesting insider trades. In particular, Ra Capital Management has been buying up IMRA stock, while 10% owner Braden Leonard has been selling. The most recent trades saw Leonard sell 1.25 million shares at $4 per share. Ra, however, purchased nearly 630,000 shares at $4.

With the potential merger looming, insider activity isn’t the only thing on the watch list. So is short interest, which Fintel shows IMRA stock’s short float at 16.83%

List Of Penny Stocks To Watch

  1. Redfin Corp. (NASDAQ: RDFN)
  2. Imara Inc. (NASDAQ: IMRA)
  3. AST SpaceMobile, Inc. (NASDAQ: ASTS)
  4. Cosmos Health Inc. (NASDAQ: COSM)
  5. 180 Life Sciences (NASDAQ: ATNF)
  6. Marathon Digital (NASDAQ: MARA)
  7. Canoo Inc. (NASDAQ: GOEV)

The post Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


The ONS has published its final COVID infection survey – here’s why it’s been such a valuable resource

The ONS’ Coronavirus Infection Survey has ceased after three years. Two experts explain why it was a uniquely useful source of data.



March 24 marked the publication of the final bulletin of the Office for National Statistics’ (ONS) Coronavirus Infection Survey after nearly three years of tracking COVID infections in the UK. The first bulletin was published on May 14 2020 and we’ve seen new releases almost every week since.

The survey was based primarily on data from many thousands of people in randomly selected households across the UK who agreed to take regular COVID tests. The ONS used the results to estimate how many people were infected with the virus in any given week.

In the survey’s first six months, we had results from 1.2 million samples taken from 280,000 people. Although the number of people participating each month declined over time, the survey has continued to be a highly valuable tool as we navigate the pandemic.

In particular, because the ONS bulletins were based on surveying a large, random sample of all UK residents, it offered the least biased surveillance system of COVID infections in the UK. We are not aware of any similar study anywhere else in the world. And, while estimating the prevalence of infections was the survey’s main output, it gave us a lot of other useful information about the virus too.

Unbiased surveillance

An important advantage of the ONS survey was its ability to detect COVID infections among many people who had no symptoms, or were not yet displaying symptoms.

Certainly other data sets existed (and some continue to exist) to give a sense of how many people were testing positive. For example, earlier in the pandemic, case numbers were reported at daily national press conferences. Figures continue to be published on the Department of Health and Social Care website.

But these totals have usually only encompassed people who tested because they had reason to suspect they may have been infected (for example because of symptoms or their work). We know many people had such minor symptoms that they had no reason to suspect they had COVID. Further, people who took a home test may or may not have reported the result.

Similarly, case counts from hospital admissions or emergency room attendances only captured a very small percentage of positive cases, even if many of these same people had severe healthcare needs.

Symptom-tracking applications such as the ZOE app or online surveys have been useful but tend to over-represent people who are most technologically competent, engaged and symptom-aware.

Testing wastewater samples to track COVID spread in a community has proved difficult to reliably link to infection numbers.

Read more: The tide of the COVID pandemic is going out – but that doesn't mean big waves still can't catch us

What else the survey told us

Aside from swab samples to test for COVID infections, the ONS survey collected blood samples from some participants to measure antibodies. This was a very useful aspect of the infection survey, providing insights into immunity against the virus in the population and individuals.

Beginning in June 2021, the ONS survey also published reports on the “characteristics of people testing positive”. Arguably these analyses were even more valuable than the simple infection rate estimates.

For example, the ONS data gave practical insights into changing risk factors from November 21 2021 to May 7 2022. In November 2021, living in a house with someone under 16 was a risk factor for testing positive but by the end of that period it seemed to be protective. Travel abroad was not an important risk factor in December 2021 but by April 2022 it was a major risk. Wearing a mask in December 2021 was protective against testing positive but by April 2022 there was no significant association.

We shouldn’t find this changing picture of risk factors particularly surprising when concurrently we had different variants emerging (during that period most notably omicron) and evolving population resistance that came with vaccination programmes and waves of natural infection.

Also, in any pandemic the value of non-pharmaceutical interventions such wearing masks and social distancing declines as the infection becomes endemic. At that point the infection rate is driven more by the rate at which immunity is lost.

A woman wearing a face mask receives a vaccine.
The survey gave us insights into the protection offered by vaccines and non-pharmaceutical interventions. Paul Maguire/Shutterstock

The ONS characteristics analyses also offered evidence about the protective effects of vaccination and prior infection. The bulletin from May 25 2022 showed that vaccination provided protection against infection but probably for not much more than 90 days, whereas a prior infection generally conferred protection for longer.

After May 2022, the focused shifted to reinfections. The analyses confirmed that even in people who had already been infected, vaccination protects against reinfection, but again probably only for about 90 days.

It’s important to note the ONS survey only measured infections and not severe disease. We know from other work that vaccination is much better at protecting against severe disease and death than against infection.

Read more: How will the COVID pandemic end?

A hugely valuable resource

The main shortcoming of the ONS survey was that its reports were always published one to three weeks later than other data sets due to the time needed to collect and test the samples and then model the results.

That said, the value of this infection survey has been enormous. The ONS survey improved understanding and management of the epidemic in the UK on multiple levels. But it’s probably appropriate now to bring it to an end in the fourth year of the pandemic, especially as participation rates have been falling over the past year.

Our one disappointment is that so few of the important findings from the ONS survey have been published in peer-reviewed literature, and so the survey has had less of an impact internationally than it deserves.

Paul Hunter consults for the World Health Organization. He receives funding from National Institute for Health Research, the World Health Organization and the European Regional Development Fund.

Julii Brainard receives funding from the NIHR Health Protection and Research Unit in Emergency Preparedness.

Read More

Continue Reading

Spread & Containment

Candida auris: what you need to know about the deadly fungus spreading through US hospitals

A drug-resistant fungus is a threat to human health.




A fungal superbug called Candida auris is spreading rapidly through hospitals and nursing homes in the US. The first case was identified in 2016. Since then, it has spread to half the country’s 50 states. And, according to a new report, infections tripled between 2019 and 2021. This is hugely concerning because Candida auris is resistant to many drugs, making this fungal infection one of the hardest to treat.

Candida auris is a yeast-type fungus that is the first to have multiple international health alerts associated with it. It has been found in over 30 countries, including the UK, since it was first identified in Japan in 2009.

It is related to other types of yeast that can cause infections, like Candida albicans which causes thrush. However, Candida auris is very different to these other fungi and in some ways, highly unusual.

First, it can grow, or “colonise”, human skin. Unlike many other Candida species that like to grow in our guts as part of the microbiome, Candida auris does not grow in this environment and seems to prefer the skin. This means that people who are colonised with Candida auris can shed lots of yeast from their skin, and this contaminates bed clothes and surfaces with the fungus. This can lead to outbreaks.

It is unusual for a fungal infection to spread from person to person, but that seems to be how Candida auris infections spread. Outbreaks can happen with this fungus, especially in intensive care units (ICU) and nursing homes where people are at a higher risk for getting fungal infections generally.

The fungus can live on surfaces for several weeks, and getting rid of it can be difficult. Enhanced cleaning and hand washing is needed to try and limit the spread of the fungus and exposure to patients who get ill from it.

Most people who are colonised with Candida auris will not get ill from it, or even know it is there. It causes infections when it gets into surgical wounds or the blood from an intravenous line. Once it gets into the body, it can infect organs and the blood causing a very serious and potentially fatal disease.

The mortality rate for people infected (as opposed to colonised) with the fungus is between 30 and 60%. But a precise mortality rate can be hard to pin down as people who are infected are often critically ill with other conditions.

Diagnosing an infection can be difficult as there can be a wide range of symptoms including fever, chills, headaches and nausea. It is for this reason that we need to keep a close eye on Candida auris as it can easily be confused with other conditions.

In the last few years, new tests to help identify this fungus accurately have been developed.

Candida auris can get into the body via an infected IV line. Tyler Olson/Shutterstock

The first Candida auris infection was reported in the UK in 2013. However, there may have been other cases before this – there is evidence that some early cases were misidentified as unrelated yeasts.

The UK has so far managed to stop any major outbreaks, and most cases have been limited in their spread.

Most patients who have become ill from Candida auris in the UK had recently travelled to parts of the world where the fungus is more common or has been circulating for longer.

Spurred by COVID

Rising numbers of Candida auris infections are thought to be partially linked to the COVID pandemic. People who become very ill from COVID may need mechanical ventilation and long stays in the ICU, which are both risk factors for Candida auris colonisation and infection.

It will take some time to figure out exactly how the pandemic has affected rates and numbers of fungal infections around the world, but these are important questions to answer to help predict how Candida auris cases might fluctuate in the future.

As for most life-threatening fungal infections, treatment is difficult and limited. We have only a handful of antifungal drugs to fight these infections, so when a species is resistant to one or more of these drugs, the options for treatment are extremely limited. Some Candida auris infections are resistant to all three types of antifungal drug.

Healthcare professionals must remain vigilant to this drug-resistant fungus. Without close monitoring and enhanced awareness of this infection, we could see more outbreaks and serious disease associated with Candida auris in the future.

Rebecca A. Drummond receives funding from the Medical Research Council.

Read More

Continue Reading

Spread & Containment

Four global problems that will be aggravated by the UK’s recent cuts to international aid

The UK is among countries cutting international aid payments, which could affect the world in four key areas: poverty, extremism, democracy and refuge…




Flags fly outside the UN building in New York. Andrew F. Kazmierski/Shutterstock

UK economic forecasts have improved markedly since the September 2022 mini-budget. The economic recession may now be more shallow and public borrowing lower than previously expected.

However, faced with persistently high inflation and continued uncertainty caused by Russia’s war in Ukraine, financial cuts remained the order of the day in the UK government’s spring 2023 budget announcement.

While Chancellor Jeremy Hunt introduced a £5 billion increase to military spending over the next two years, the international aid budget was cut for the third time in three years. This is part of an increasingly concerning international trend.

UK aid has been deceasing since 2019. And the country is not alone in cutting its aid commitments. Sweden – one of the world’s leading donors in this area – is also set to abolish its target of spending 1% of GDP on aid. Across several European countries, recent cuts have largely been driven by the Ukraine war, as well as national pressures caused by the COVID pandemic.

And yet aid is sorely needed if the world is to meet the 2030 Agenda for Sustainable Development, a plan to end world poverty agreed by UN members in 2015. The “great finance divide” – which sees some countries struggle to access resources and affordable finance for economic investment – continues to grow, according to the UN, leaving developing countries in Asia, Africa and Latin America more susceptible to shocks.

The UK and Europe’s support for Ukraine is admirable and much-needed. But when countries are faced with important domestic political and financial challenges, governments tend to look inwards – often in an attempt to rally their electorate.

Cuts to aid budgets are one example of this. For the UK in particular, neglecting multilateral solutions to important global challenges could actually exacerbate what are thought of as “domestic issues”. Our research highlights four such issues that could be affected by the UK’s budget cuts.

1. Increasing poverty could affect global stability

While the exact direction of the relationship remains up for debate, poverty is an important cause and effect of war. We know that up to two-thirds of the world’s extreme poor (defined as people earning less than $1.90 a day) will be concentrated in fragile and conflict-affected countries by 2030.

Research shows that aid promotes economic growth. So, reducing international aid will only exacerbate these recent negative trends. According to the chief executive of Oxfam GB, aid is an investment in a more stable world – something that is in all of our interests.

2. Extremism could spread as western influence falls

Violent extremism is on the rise in Africa. It reduces international investment and undermines the rights of minority groups, women and girls. This goes against important UN sustainable development goals aimed at building peace and prosperity for the planet and its people.

Reducing international aid will create opportunities for new political actors to emerge and influence the direction of countries with weak government institutions. Cutting back western influence in international architecture (especially while these countries support a conflict in their own continent) may also be resented by countries in other parts of the world that would like more support.

3. Democracy could be threatened in some countries

When aid is provided in the right way, it can give a boost to democratic outcomes. Again, if western, democratic and liberal states don’t support countries struggling to tackle poverty and extremism, other actors could step in.

Russia’s increasing involvement in the Central African Republic and Burkina Faso are recent examples. Equally, China’s Belt and Road Initiative (through which it lends money to other countries to build infrastructure) has significantly broadened its economic and political influence in many parts of the world. But some experts fear that China is laying a debt trap for borrowing governments, whereby the contracts agreed allow it to seize strategic assets when debtor countries run into financial problems.

The growing influence of both states may explain global trends towards democratic backsliding because research shows democratic stability is often undermined in waves. In recent UN votes, Russia and China’s growing influence via such aid has been seen to bear fruit. For example, in October 2022 Uzbekistan and Kazakhstan –- both temporary members of the UN Human Rights council –- voted against a decision to discuss human rights concerns in China’s Muslim-majority Xinjiang region.

4. More countries could struggle to welcome refugees

People flee their homes for many reasons but mostly due to conflict, violent extremism and poverty. Most refugees do not travel to western countries such as the UK, although the number of people arriving in small boats across the English Channel has risen substantially recently.

But there are more “internationally displaced people” than refugees. That is, most people fleeing war remain in their country, while refugees tend to remain in neighbouring states.

Turkey receives the highest numbers of refugees due to its proximity to the ongoing war in Syria, and Poland welcomed the highest number of refugees fleeing the war in Ukraine.

This, combined with the fact that countries most likely to experience conflict are geographically distant from the UK, indicates that numbers seeking asylum in the UK will remain relatively low. But reducing aid will impose further pressures on poor countries that are already struggling to accommodate refugee flows, as well as increasing push factors for migration from fragile regions.

International aid should be one of many solutions

Failure to tackle global problems like poverty, extremism, and democratic backsliding could further destabilise fragile regions. This will have human costs including increased numbers of desperate people attempting to cross the channel.

Aid is an investment in a more stable world. Deals with France or the risk of deportation to Rwanda will have limited impact on reducing the number of people arriving on small boats if the root causes of their migration are not tackled.

In our globalised world, looking inwards can only exacerbate these problems. It is crucial that states adopt multilateral solutions – including funding international aid programmes – to tackle global problems.

Patricia Justino receives funding from the UK Economic and Social Research Council.

Kit Rickard does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading